{"id":"W2922237910","doi":"10.1182/blood-2018-11-880526","title":"Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":136,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"Cilag; Pharmacyclics; National Cancer Institute; H. Lundbeck A/S; Servier; Amgen; TG Therapeutics; Genentech; Celgene; Gilead Sciences; F. Hoffmann-La Roche","keywords":"Venetoclax; CHOP; Medicine; Internal medicine; Lymphoma; Radioimmunotherapy; Oncology; Cancer research; Immunology; Leukemia; Chronic lymphocytic leukemia; Antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001646175,0.00062202,0.000852919,0.0002084738,0.0002271605,0.0007933514,0.0005411312,0.0007151932,0.00280615],"category_scores_gemma":[0.0009745971,0.0002434129,0.0007948353,0.0003090179,0.0005818881,0.0004868395,0.0002013973,0.002180077,0.000381021],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006372131,"about_ca_system_score_gemma":0.0006857956,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001285444,"about_ca_topic_score_gemma":0.003412852,"domain_scores_codex":[0.9995717,0.000277058,0.00001580353,0.00004961554,0.00003601475,0.00004971965],"domain_scores_gemma":[0.9993424,0.0002155878,0.0001281445,0.00006297701,0.00003732282,0.0002135971],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8072777,0.01362555,0.006854495,0.001858309,0.001979177,0.0002150241,0.0002026587,0.001935379,0.02165007,0.0004946542,0.009643639,0.1342633],"study_design_scores_gemma":[0.8068226,0.1583442,0.02284728,0.0001902486,0.001050277,0.0003120172,0.00008416023,0.001841884,0.002737006,0.000372617,0.005364549,0.00003318691],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9815421,0.01210722,0.0002848638,0.0008338134,0.0001915382,0.0006457365,0.0008792432,0.000108613,0.00340678],"genre_scores_gemma":[0.9888861,0.003957058,0.0008685279,0.00093544,0.0002814061,0.0004839453,0.001887408,0.00002971327,0.002670459],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00280615,"threshold_uncertainty_score":0.009387553,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0250096202725218,"score_gpt":0.2999874654202687,"score_spread":0.2749778451477469,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}